214 related articles for article (PubMed ID: 25088577)
1. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
3. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
4. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
5. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
7. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
8. TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.
Drube S; Weber F; Göpfert C; Loschinski R; Rothe M; Boelke F; Diamanti MA; Löhn T; Ruth J; Schütz D; Häfner N; Greten FR; Stumm R; Hartmann K; Krämer OH; Dudeck A; Kamradt T
Oncotarget; 2015 Oct; 6(30):28833-50. PubMed ID: 26353931
[TBL] [Abstract][Full Text] [Related]
9. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
[TBL] [Abstract][Full Text] [Related]
10. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
[TBL] [Abstract][Full Text] [Related]
11. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
Chan IJ; Kasprowicz S; Tharp MD
Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
[TBL] [Abstract][Full Text] [Related]
13. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
Hara Y; Obata Y; Horikawa K; Tasaki Y; Suzuki K; Murata T; Shiina I; Abe R
PLoS One; 2017; 12(4):e0175514. PubMed ID: 28403213
[TBL] [Abstract][Full Text] [Related]
14. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
15. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
16. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
17. Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
Lee S; Lee H; Kim J; Lee S; Kim SJ; Choi BS; Hong SS; Hong S
J Med Chem; 2014 Aug; 57(15):6428-43. PubMed ID: 25004409
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Cerny-Reiterer S; Rabenhorst A; Stefanzl G; Herndlhofer S; Hoermann G; Müllauer L; Baumgartner S; Beham-Schmid C; Sperr WR; Mannhalter C; Sill H; Linkesch W; Arock M; Hartmann K; Valent P
Oncotarget; 2015 Feb; 6(5):3071-84. PubMed ID: 25605011
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]